Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 2Ovarian Neoplasms 2Lung Neoplasms 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Salivary Gland Neoplasms 1Rhabdomyosarcoma, Alveolar 1Penile Neoplasms 1Oropharyngeal Neoplasms 1Neoplasm Metastasis 1Mouth Neoplasms 1Mesothelioma, Malignant 1Lymphoma 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Carcinoma, Neuroendocrine 1Carcinoma 1

Interventions

Carboplatin 29Paclitaxel 22Taxes 16Bevacizumab 15Specimen Handling 10Immunoglobulin G 10Disulfides 10Magnetic Resonance Spectroscopy 9Gemcitabine 9Biopsy 9veliparib 8olaparib 8liposomal doxorubicin 7cediranib 6Doxorubicin 6Docetaxel 6Topotecan 5Chemotherapy, Adjuvant 4Oxaliplatin 3Immunohistochemistry 3Gene Expression Profiling 3temsirolimus 2reolysin 2oregovomab 2ipatasertib 2cabozantinib 2berzosertib 2belinostat 2atezolizumab 2aflibercept 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Fallopian Tube Neoplasms × BAY 1895344 × Clear all
NCT04616534 2025-05-22

Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors

National Cancer Institute (NCI)

Phase 1 Active not recruiting
14 enrolled
GastrointestinalGynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡